Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.79 |
| ▸ | KIT | P10721 | 10/20 | 0.79 |
| ▸ | KDR | P35968 | 8/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.79 |
| ▸ | LCK | P06239 | 5/20 | 0.79 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.79 |
| ▸ | LYN | P07948 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398050 | 1.00 | MAPK14 (0.79) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL397175 | 1.00 | MAPK14 (0.79) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL397312 | 0.93 | MAPK14 (0.79) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL397124 | 0.91 | MAPK14 (0.77) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL398047 | 0.90 | MAPK14 (0.76) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL1406009 | 0.90 | MAPK14 (0.77) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL1406123 | 0.90 | MAPK14 (0.77) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL395839 | 0.89 | MAPK14 (0.75) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL395416 | 0.89 | MAPK14 (0.75) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL396376 | 0.89 | MAPK14 (0.73) | MAPK14KITKDRMAPK9LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101612-B2 | N-3-isoxazolyl-4-methyl-3-(1-((1-methylethyl)oxy)-6-phthalazinyl)benzamide; p38 kinase inhibitor; antiinflammatory, analgesic agent; rheumatoid arthritis, osteoporosis, leukemia, psoriasis, Crohn's disease, rhinitis, ulcerative colitis, dermatitis, asthma, Alzheimer's disease, type I and II diabetes | AMGEN INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-2077998-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2011-03-09 | — | — | EP | claimed |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2008-05-22 | — | — | US | claimed |
| US-8101612-B2 | N-3-isoxazolyl-4-methyl-3-(1-((1-methylethyl)oxy)-6-phthalazinyl)benzamide; p38 kinase inhibitor; antiinflammatory, analgesic agent; rheumatoid arthritis, osteoporosis, leukemia, psoriasis, Crohn's disease, rhinitis, ulcerative colitis, dermatitis, asthma, Alzheimer's disease, type I and II diabetes | AMGEN INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2077998-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | MAPK14 293/4885KIT 1977/4885KDR 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.